22,000 Shares in Novo Nordisk A/S (NYSE:NVO) Bought by Inspire Trust Co. N.A.

Inspire Trust Co. N.A. bought a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 22,000 shares of the company's stock, valued at approximately $1,892,000.

Several other large investors have also recently bought and sold shares of the company. Center for Financial Planning Inc. boosted its position in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after buying an additional 123 shares during the period. Strategic Investment Solutions Inc. IL lifted its holdings in shares of Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after purchasing an additional 300 shares during the last quarter. Transce3nd LLC bought a new stake in Novo Nordisk A/S in the fourth quarter worth $33,000. Kelly Lawrence W & Associates Inc. CA purchased a new stake in Novo Nordisk A/S during the 4th quarter valued at about $39,000. Finally, Albion Financial Group UT increased its holdings in shares of Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after purchasing an additional 278 shares in the last quarter. 11.54% of the stock is owned by institutional investors.

Analysts Set New Price Targets

NVO has been the subject of several analyst reports. BNP Paribas started coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating for the company. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Finally, Wall Street Zen raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Novo Nordisk A/S currently has an average rating of "Moderate Buy" and a consensus target price of $135.00.

Novo Nordisk A/S Stock Performance

NYSE:NVO traded down $0.91 during trading hours on Monday, reaching $67.26. 6,502,571 shares of the company's stock were exchanged, compared to its average volume of 6,701,288. The company has a 50-day moving average of $66.31 and a 200 day moving average of $82.74. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $148.15. The firm has a market capitalization of $301.83 billion, a price-to-earnings ratio of 20.44, a P/E/G ratio of 0.90 and a beta of 0.65. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.